Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glucagon-like Peptide 1 Market Report 2026" has been added to ResearchAndMarkets.com's offering. The glucagon-like peptide 1 (GLP-1) market has witnessed ...
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...
Since the pioneering discovery of secretin-like activity by Bayliss and Starling in 1902, scientists have pursued the mysteries of gut-hormone biology, such that the peptide hormone–secreting ...
In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications, ...
Clinical Trials Arena on MSN
Structure’s obesity pill prompts 16.3% weight loss in Phase II
Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare ...
Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results